相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。OCEAN: a randomized Phase III study of melflufen plus dexamethasone to treat relapsed refractory multiple myeloma
Fredrik Schjesvold et al.
FUTURE ONCOLOGY (2020)
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
Sagar Lonial et al.
LANCET ONCOLOGY (2020)
Multiple Myeloma: Available Therapies and Causes of Drug Resistance
Vanessa Pinto et al.
CANCERS (2020)
Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study
Paul G. Richardson et al.
LANCET HAEMATOLOGY (2020)
Pomalidomide-dexamethasone for treatment of soft-tissue plasmacytomas in patients with relapsed/refractory multiple myeloma
Raquel Jimenez-Segura et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2019)
Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy
Ujjawal H. Gandhi et al.
LEUKEMIA (2019)
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
Noopur Raje et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma
Ajai Chari et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
A Phase 1b/2a Study of the CELMoD Iberdomide (CC-220) in Combination With Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
Sagar Lonial et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2019)
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
Michel Attal et al.
LANCET (2019)
Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond
C. S. Chim et al.
LEUKEMIA (2018)
Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting
Paul G. Richardson et al.
BLOOD CANCER JOURNAL (2018)
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study
S. K. Kumar et al.
LEUKEMIA (2017)
Melflufen - a peptidase-potentiated alkylating agent in clinical trials
Malin Wickstrom et al.
ONCOTARGET (2017)
Management of multiple myeloma in the relapsed/refractory patient
Pieter Sonneveld
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2017)
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
P. Moreau et al.
ANNALS OF ONCOLOGY (2017)
Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma
Saad Z. Usmani et al.
BLOOD (2016)
Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma
Meletios A. Dimopoulos et al.
BLOOD (2016)
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
Pieter Sonneveld et al.
BLOOD (2016)
A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells
Arghya Ray et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
A multicenter phase 2 study of pomalidomide plus dexamethasone in patients with relapsed and refractory multiple myeloma: the Japanese MM-011 trial
Tatsuo Ichinohe et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2016)
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
Jesus F. San-Miguel et al.
LANCET ONCOLOGY (2014)
The novel alkylating prodrug melflufen (J1) inhibits angiogenesis in vitro and in vivo
Sara Strese et al.
BIOCHEMICAL PHARMACOLOGY (2013)
In Vitro and In Vivo Antitumor Activity of a Novel Alkylating Agent, Melphalan-Flufenamide, against Multiple Myeloma Cells
Dharminder Chauhan et al.
CLINICAL CANCER RESEARCH (2013)
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1
S. Vincent Rajkumar et al.
BLOOD (2011)
Aminopeptidase N (CD13) as a target for cancer chemotherapy
Malin Wickstrom et al.
CANCER SCIENCE (2011)
Aminopeptidase inhibition as a targeted treatment strategy in myeloma
Hannah E. Moore et al.
MOLECULAR CANCER THERAPEUTICS (2009)
The novel alkylating prodrug J1: diagnosis directed activity profile ex vivo and combination analyses in vitro
Malin Wickstroem et al.
INVESTIGATIONAL NEW DRUGS (2008)
分享论文
